Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the impact of treatment of anemia with darbepoetin
alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular
events, and (2) progression to end-stage renal disease or death, in subjects with chronic
kidney disease and type 2 diabetes mellitus.
Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD